1. Home
  2. LSTA vs PMN Comparison

LSTA vs PMN Comparison

Compare LSTA & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LSTA
  • PMN
  • Stock Information
  • Founded
  • LSTA 1980
  • PMN 2004
  • Country
  • LSTA United States
  • PMN Canada
  • Employees
  • LSTA N/A
  • PMN N/A
  • Industry
  • LSTA Misc Health and Biotechnology Services
  • PMN Pharmaceuticals and Biotechnology
  • Sector
  • LSTA Health Care
  • PMN Health Care
  • Exchange
  • LSTA Nasdaq
  • PMN Nasdaq
  • Market Cap
  • LSTA 31.2M
  • PMN 29.8M
  • IPO Year
  • LSTA N/A
  • PMN N/A
  • Fundamental
  • Price
  • LSTA $2.61
  • PMN $0.96
  • Analyst Decision
  • LSTA Strong Buy
  • PMN
  • Analyst Count
  • LSTA 1
  • PMN 0
  • Target Price
  • LSTA $15.00
  • PMN N/A
  • AVG Volume (30 Days)
  • LSTA 66.3K
  • PMN 43.3K
  • Earning Date
  • LSTA 02-27-2025
  • PMN 03-31-2025
  • Dividend Yield
  • LSTA N/A
  • PMN N/A
  • EPS Growth
  • LSTA N/A
  • PMN N/A
  • EPS
  • LSTA N/A
  • PMN N/A
  • Revenue
  • LSTA N/A
  • PMN N/A
  • Revenue This Year
  • LSTA N/A
  • PMN N/A
  • Revenue Next Year
  • LSTA N/A
  • PMN N/A
  • P/E Ratio
  • LSTA N/A
  • PMN N/A
  • Revenue Growth
  • LSTA N/A
  • PMN N/A
  • 52 Week Low
  • LSTA $2.19
  • PMN $0.87
  • 52 Week High
  • LSTA $4.20
  • PMN $2.61
  • Technical
  • Relative Strength Index (RSI)
  • LSTA 42.17
  • PMN 56.16
  • Support Level
  • LSTA $2.45
  • PMN $0.90
  • Resistance Level
  • LSTA $2.74
  • PMN $0.95
  • Average True Range (ATR)
  • LSTA 0.32
  • PMN 0.06
  • MACD
  • LSTA -0.05
  • PMN 0.01
  • Stochastic Oscillator
  • LSTA 16.48
  • PMN 67.79

About LSTA Lisata Therapeutics Inc.

Lisata Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Its product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively.

About PMN ProMIS Neurosciences Inc. (ON)

ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine is based on the use of two complementary techniques. The company applies its thermodynamic, computational discovery platform-ProMIS and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.

Share on Social Networks: